HBM Healthcare Investments, an investment company specializing in the healthcare sector, successfully closed its 2025/2026 financial year as of 31 March. Over the course of the year, the net asset value (NAV) in Swiss francs increased by 17.2 percent (29.2 percent in US Dollars), while the share price recorded an increase of 28.5 percent.

In addition to the constructive capital market environment for the biotechnology sector, the positive result was driven in particular by several value‑enhancing transactions involving both private and publicly listed portfolio companies. During the financial year under review, a total of seven portfolio companies — Merus, Y‑mAbs Therapeutics, 89Bio, Akero, Bluejay Therapeutics, Swixx Biopharma, and Terns Pharmaceuticals — were acquired by pharmaceutical companies or financial investors.

By contrast, the strong appreciation of the Swiss franc against the Company’s main investment currencies had a noticeable negative impact on the annual result.

The figures presented are preliminary and unaudited, based on the current status of the year‑end closing process. The final annual results will be published with the 2025/2026 Annual Report on 13 May 2026.